BioSpace News Archive

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced positive efficacy data from a study of its induced pluripotent stem cell -derived Cymerus™ mesenchymal stem cells in a preclinical rodent model of idiopathic pulmonary fibrosis.

Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30 per cent and significantly slowed kidney function decline1

Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19.

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that it has closed on an initial $3 million in a Series B-1 financing with total approved capital of up to $6 mi

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it will provide a corporate update at the 22 nd HC Wainwright Annual Global Investment Conference. The conference will take place virtually September 14 – 16, 2020.

“Simple and Affordable Salt Spray Uses Everyday Household Ingredients to Help Protect You Against the Coronavirus” As Featured on FOX 26 Houston

Clene Nanomedicine, Inc., (“Clene”) a clinical-stage biopharmaceutical company and its Australian subsidiary, Clene Australia Pty Ltd., today announced the completion of patient enrollment in its RESCUE-ALS Phase 2 study.

Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Frasier, president and chief executive officer, will present at the H.C. Wainwright 22 nd Annual Global Inve

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its sixth annual STRIVE Awards grant program for Duchenne muscular dystrophy.